Hepatic Targeting Nanoparticles for TRβ1 Agonist Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia and obesity, such as statins, can cause liver damage and have adverse effects, and thyroid receptor beta1 (TRβ1) agonists like GC-1 and KB2115, while effective in lowering cholesterol, have shown unwanted side effects like cartilage damage in long-term exposure, limiting their therapeutic use.
Innovation Solution
Development of nano-hepatic targeting mechanisms using hydrophobic nanoparticles, such as chitosan hybrid, PLGA, and solid lipid nanoparticles, conjugated with liver-targeting moieties like Glycyrrhetinic acid and Lactobionic acid, to deliver TRβ1 agonists selectively to the liver, minimizing systemic distribution and potential side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRβ1 agonists are administered systemically to lower cholesterol, then LDL-cholesterol reduction is achieved, but systemic side effects such as cartilage damage occur
Solution Approach 1:
The patent segments the drug delivery system by dividing the TRβ1 agonist administration into two distinct components: (1) nanoparticle carriers that encapsulate the agonist, and (2) liver-specific targeting moieties that direct the nanoparticles to hepatic tissue. This segmentation allows the drug to be delivered locally to the liver rather than systemically, achieving cholesterol lowering while avoiding widespread side effects.
Solution Approach 2:
The patent introduces nanoparticles as an intermediary carrier between the TRβ1 agonist and the liver tissue. These nanoparticles serve as a mediator that transports the drug specifically to hepatic cells through surface conjugated targeting moieties, thereby reducing direct systemic exposure and minimizing adverse effects on non-target tissues such as cartilage.
2Reliability
If higher doses of TRβ1 agonists are used to achieve greater cholesterol reduction, then therapeutic efficacy is improved, but adverse effects increase
Solution Approach 1:
The patent applies local quality by concentrating the TRβ1 agonist delivery specifically in the liver through targeted nanoparticle accumulation. The liver receives a high local concentration of the drug needed for effective cholesterol lowering, while other tissues receive minimal to no exposure. This localized high-dose delivery achieves therapeutic efficacy without proportionally increasing systemic adverse effects.
3Reliability
If statins are administered to reduce cardiovascular risk, then mortality is reduced, but liver damage occurs
Solution Approach 1:
The patent changes the fundamental parameter of drug delivery from non-targeted systemic administration to targeted hepatic delivery. By altering the delivery route and target specificity, the same therapeutic goal (cholesterol lowering for cardiovascular protection) is achieved through a different mechanism that spares the liver from the toxic effects associated with statin therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nano-hepatic targeting approach enhances the safety and efficacy of TRβ1 agonists by achieving significant LDL-cholesterol reduction with reduced systemic exposure and adverse effects, allowing for effective treatment of dyslipidemia and obesity at lower doses.
Implementation Method 1
hydrophobic nanoparticles, wherein the nanoparticles are selected from the group consisting of chitosan hybrid nanoparticles, amine-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles, solid lipid nanoparticles
Implementation Method 2
a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, said liver targeting moiety selected from the group consisting of Glycyrrhetinic acid (GA), Lactobionic acid (LA), and combinations thereof
Data Source
AI summary
A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.